December 2016
-
According to Avanir Pharmaceuticals, the company has submitted a 505(b)(2) New Drug Application (NDA) for its AVP-825 intranasal dry powder sumatriptan for the treatment of migraine to the FDA. Avanir acquired the North American license… Read more . . .
-
Romania has approved the 50 µg/500 µg dose version of Sandoz’s AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD, triggering a €1.5 million milestone payment to Vectura. The inhaler has also been… Read more . . .
-
Copley Scientific has announced the launch of its BAC 2000 breath actuated controller and BRS 1100 breathing simulator for the testing of MDIs with spacers and valved holding chambers in accordance with draft US Pharmacopoeia… Read more . . .
-
Prosonix has announced that a Phase 2 clinical study of its PSX1002 glycopyrronium bromide MDI in 37 COPD patients demonstrated statistically significant improvement in lung function compared to placebo for a range of doses. PSX1002… Read more . . .
-
Evoke Pharma has published a Phase 2b study demonstrating superior efficacy of intranasal metoclopramide compared to oral metoclopramide for the management of diabetic gastroparesis symptoms. The study appears in an upcoming issue of Neurogastroenterology &… Read more . . .
-
Skyepharma has announced that Spain has completed a mutual recognition procedure regarding Flutiform fluticasone propionate/formoterol fumarate MDI for the treatment of asthma. The European Commission approved Flutiform in July 2012. The company also said that… Read more . . .
-
Vivaldi Biosciences has signed an agreement with the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) for co-research and development of live attenuated influenza vaccine (LAIV) candidates against the H7N9 strain of influenza A.… Read more . . .
-
Sandoz has announced that it received marketing authorization for the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD from Sweden and Hungary. The company’s version of Advair has also been approved by… Read more . . .
-
A new, or at least new-ish, contract development and manufacturing company called Formex LLC launched on March 8, 2013 after its parent company, Biotech Investment Group (B.I.G.), acquired all of the assets formerly belonging to… Read more . . .
-
PPD, Middleton (Madison) WI. Key Accountabilities and responsibilities: • Proactively scan the external environment to identify and evaluate scientific and technological developments relevant to the Inhalation business. • Develop information exchanges with biotechnology companies, pharmaceutical… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland